Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Mar;114(5):949–954. doi: 10.1111/j.1476-5381.1995.tb13296.x

Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats.

T Watanabe 1, Y Awane 1, S Ikeda 1, S Fujiwara 1, K Kubo 1, T Kikuchi 1, K Kusumoto 1, M Wakimasu 1, M Fujino 1
PMCID: PMC1510321  PMID: 7780649

Abstract

1. The aims of the present study were to characterize the pharmacological profile of a new endothelin (ET) receptor antagonist, TAK-044 and to consider whether it limits the extension of myocardial infarct size in rats. 2. Binding of [125I]-ET-1 to ET receptors on rabbit ventricular and cerebellar membrane fractions was inhibited by TAK-044 with IC50 values of 3.8 nM and 130 nM, respectively. 3. It inhibited ET-1, ET-2 and ET-3-induced vasoconstriction of porcine isolated coronary arteries in a competitive (ET-1, ET-2) and a non-competitive (ET-3) manner. 4. In the rat in vivo, the ET-1-induced blood pressure changes including transient hypotension followed by sustained hypertension, were inhibited by TAK-044 (0.1-10 mg kg-1, i.v.) in a dose-dependent manner. 5. Acute myocardial infarction induced by 1 h coronary occlusion followed by 24 h reperfusion in rats caused an infarct size of 60 +/- 2% (n = 12) of the area-at-risk by weight. 6. Intravenous injection of TAK-044 10 min before coronary occlusion reduced the infarct size in a dose-dependent manner: 32% and 54% reductions at 1 and 3 mg kg-1, respectively. 7. TAK-044 administered 10 min before or 1 h after reperfusion (1 mg kg-1, i.v.) showed similar inhibitory effects: 34% and 23% reductions, respectively. 8. We conclude that TAK-044 is an ETA/ETB receptor antagonist which shows strong inhibitory effects on the extension of myocardial infarct size after coronary artery occlusion-reperfusion in rats.

Full text

PDF
949

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  2. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  3. Clozel M., Gray G. A., Breu V., Löffler B. M., Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992 Jul 31;186(2):867–873. doi: 10.1016/0006-291x(92)90826-7. [DOI] [PubMed] [Google Scholar]
  4. Glossmann H., Ferry D. R. Assay for calcium channels. Methods Enzymol. 1985;109:513–550. doi: 10.1016/0076-6879(85)09112-1. [DOI] [PubMed] [Google Scholar]
  5. Grover G. J., Dzwonczyk S., Parham C. S. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 1993 Sep;27(9):1613–1618. doi: 10.1093/cvr/27.9.1613. [DOI] [PubMed] [Google Scholar]
  6. Haynes W. G., Webb D. J. The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) 1993 May;84(5):485–500. doi: 10.1042/cs0840485. [DOI] [PubMed] [Google Scholar]
  7. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  8. Kikuchi T., Ohtaki T., Kawata A., Imada T., Asami T., Masuda Y., Sugo T., Kusumoto K., Kubo K., Watanabe T. Cyclic hexapeptide endothelin receptor antagonists highly potent for both receptor subtypes ETA and ETB. Biochem Biophys Res Commun. 1994 May 16;200(3):1708–1712. doi: 10.1006/bbrc.1994.1649. [DOI] [PubMed] [Google Scholar]
  9. Kusumoto K., Awane Y., Fujiwara S., Watanabe T. Role of endogenous endothelin in extension of rabbit myocardial infarction. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S339–S342. doi: 10.1097/00005344-199322008-00089. [DOI] [PubMed] [Google Scholar]
  10. Kusumoto K., Kubo K., Kandori H., Kitayoshi T., Sato S., Wakimasu M., Watanabe T., Fujino M. Effects of a new endothelin antagonist, TAK-044, on post-ischemic acute renal failure in rats. Life Sci. 1994;55(4):301–310. doi: 10.1016/0024-3205(94)00732-2. [DOI] [PubMed] [Google Scholar]
  11. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  12. Masaki T., Yanagisawa M., Goto K. Physiology and pharmacology of endothelins. Med Res Rev. 1992 Jul;12(4):391–421. doi: 10.1002/med.2610120405. [DOI] [PubMed] [Google Scholar]
  13. Masaoka H., Suzuki R., Hirata Y., Emori T., Marumo F., Hirakawa K. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet. 1989 Dec 9;2(8676):1402–1402. doi: 10.1016/s0140-6736(89)92019-9. [DOI] [PubMed] [Google Scholar]
  14. McMurdo L., Corder R., Thiemermann C., Vane J. R. Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol. 1993 Feb;108(2):557–561. doi: 10.1111/j.1476-5381.1993.tb12840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McMurdo L., Thiemermann C., Vane J. R. The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. Br J Pharmacol. 1994 May;112(1):75–80. doi: 10.1111/j.1476-5381.1994.tb13032.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mino N., Kobayashi M., Nakajima A., Amano H., Shimamoto K., Ishikawa K., Watanabe K., Nishikibe M., Yano M., Ikemoto F. Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats. Eur J Pharmacol. 1992 Oct 6;221(1):77–83. doi: 10.1016/0014-2999(92)90774-x. [DOI] [PubMed] [Google Scholar]
  17. Miyauchi T., Yanagisawa M., Tomizawa T., Sugishita Y., Suzuki N., Fujino M., Ajisaka R., Goto K., Masaki T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989 Jul 1;2(8653):53–54. doi: 10.1016/s0140-6736(89)90303-6. [DOI] [PubMed] [Google Scholar]
  18. Molenaar P., O'Reilly G., Sharkey A., Kuc R. E., Harding D. P., Plumpton C., Gresham G. A., Davenport A. P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993 Mar;72(3):526–538. doi: 10.1161/01.res.72.3.526. [DOI] [PubMed] [Google Scholar]
  19. Saito Y., Nakao K., Mukoyama M., Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med. 1990 Jan 18;322(3):205–205. doi: 10.1056/nejm199001183220315. [DOI] [PubMed] [Google Scholar]
  20. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  21. Shibouta Y., Suzuki N., Shino A., Matsumoto H., Terashita Z., Kondo K., Nishikawa K. Pathophysiological role of endothelin in acute renal failure. Life Sci. 1990;46(22):1611–1618. doi: 10.1016/0024-3205(90)90392-5. [DOI] [PubMed] [Google Scholar]
  22. Sogabe K., Nirei H., Shoubo M., Nomoto A., Ao S., Notsu Y., Ono T. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1993 Mar;264(3):1040–1046. [PubMed] [Google Scholar]
  23. Sudjarwo S. A., Hori M., Takai M., Urade Y., Okada T., Karaki H. A novel subtype of endothelin B receptor mediating contraction in swine pulmonary vein. Life Sci. 1993;53(5):431–437. doi: 10.1016/0024-3205(93)90647-l. [DOI] [PubMed] [Google Scholar]
  24. Sumner M. J., Cannon T. R., Mundin J. W., White D. G., Watts I. S. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol. 1992 Nov;107(3):858–860. doi: 10.1111/j.1476-5381.1992.tb14537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Teerlink J. R., Breu V., Sprecher U., Clozel M., Clozel J. P. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res. 1994 Jan;74(1):105–114. doi: 10.1161/01.res.74.1.105. [DOI] [PubMed] [Google Scholar]
  26. Tomita K., Ujiie K., Nakanishi T., Tomura S., Matsuda O., Ando K., Shichiri M., Hirata Y., Marumo F. Plasma endothelin levels in patients with acute renal failure. N Engl J Med. 1989 Oct 19;321(16):1127–1127. doi: 10.1056/NEJM198910193211615. [DOI] [PubMed] [Google Scholar]
  27. Urade Y., Fujitani Y., Oda K., Watakabe T., Umemura I., Takai M., Okada T., Sakata K., Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [Cys11-Cys15]-endothelin-1(11-21) FEBS Lett. 1992 Oct 12;311(1):12–16. doi: 10.1016/0014-5793(92)81355-p. [DOI] [PubMed] [Google Scholar]
  28. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991 Aug;69(2):370–377. doi: 10.1161/01.res.69.2.370. [DOI] [PubMed] [Google Scholar]
  29. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Endothelin in myocardial infarction. Nature. 1990 Mar 8;344(6262):114–114. doi: 10.1038/344114a0. [DOI] [PubMed] [Google Scholar]
  30. Williams D. L., Jr, Jones K. L., Pettibone D. J., Lis E. V., Clineschmidt B. V. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun. 1991 Mar 15;175(2):556–561. doi: 10.1016/0006-291x(91)91601-8. [DOI] [PubMed] [Google Scholar]
  31. Winkles J. A., Alberts G. F., Brogi E., Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun. 1993 Mar 31;191(3):1081–1088. doi: 10.1006/bbrc.1993.1327. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES